Last reviewed · How we verify
NCT07417189
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Phase 1, PHASE2 trial testing ABSK141-400mg in Solid Tumors, Adult in 401 participants. Currently enrolling.
30 December 2028
Quick facts
| Lead sponsor | Abbisko Therapeutics Co, Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 401 |
| Start date | 2 March 2026 |
| Primary completion | 30 December 2028 |
| Estimated completion | 30 July 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- ABSK141-400mg — full drug profile →
- ABSK141-Recommended Dose for Expansion (RDE) — full drug profile →
- ABSK141-800mg — full drug profile →
- ABSK141-1200mg — full drug profile →
- ABSK141-Recommended Phase 2 dose (RP2D) — full drug profile →
Conditions studied
- Solid Tumors, Adult — all drugs for Solid Tumors, Adult →
Sponsor
Abbisko Therapeutics Co, Ltd — full company profile →
Who can join
18 and older, any sex, with Solid Tumors, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07417189
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumors, Adult
Currently open trials in the same condition.
- NCT07396584 — HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07228247 — A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06504368 — Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors · Phase 1 · recruiting
- NCT05861895 — HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors · Phase 1 · recruiting
- NCT06404528 — Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours · NA · recruiting
Other Abbisko Therapeutics Co, Ltd trials
Trials by the same sponsor.
- NCT07297875 — A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia · Phase 1, PHASE2 · not yet recruiting
- NCT07164170 — A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib · Phase 2 · not yet recruiting
- NCT07210996 — A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions i · Phase 1 · completed
- NCT07288957 — A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting
- NCT07301463 — A Study in Children With Achondroplasia · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07417189 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbisko Therapeutics Co, Ltd
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07417189.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing